SCHEMBL653119

SCHEMBL653119

COc1ccc(/N=C2/NC(=O)/C(=C/c3cnc(NC(=O)CCC(=O)O)s3)S2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
MEN1 O00255 8/20 0.50
KMT2A Q03164 8/20 0.50
POLB P06746 6/20 0.49
HPGD P15428 2/20 0.49
MAPK1 P28482 2/20 0.49
ALOX5 P09917 1/20 0.49
PTPN7 P35236 2/20 0.47
DUSP3 P51452 2/20 0.47
PTPN12 Q05209 2/20 0.47
PTPN22 Q9Y2R2 2/20 0.47
PTPN11 Q06124 2/20 0.47
PTPN5 P54829 1/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
RECQL P46063 2/20 0.47
BLM P54132 2/20 0.47
APEX1 P27695 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SAE1 Q9UBE0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653120 1.00 MAPT (0.52) MAPTMEN1KMT2APOLBHPGD
SCHEMBL649726 0.90 SYK (0.48) MAPTMEN1KMT2APOLBMAPK1
SCHEMBL650807 0.90 SYK (0.48) MAPTMEN1KMT2APOLBMAPK1
SCHEMBL653260 0.89 NPC1 (0.50) MAPTMEN1KMT2APOLBPTPN7
SCHEMBL653261 0.89 NPC1 (0.50) MAPTMEN1KMT2APOLBPTPN7
SCHEMBL651435 0.89 POLB (0.54) MAPTMEN1KMT2APOLBHPGD
SCHEMBL651434 0.89 POLB (0.54) MAPTMEN1KMT2APOLBHPGD
SCHEMBL649044 0.89 MEN1 (0.46) MAPTMEN1KMT2APOLBHPGD
SCHEMBL649045 0.89 MEN1 (0.46) MAPTMEN1KMT2APOLBHPGD
SCHEMBL653571 0.88 MEN1 (0.42) MAPTMEN1KMT2APOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885MEN1 1406/4885KMT2A 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.